drugset
drugset / Trial / NCT00822835

Study Evaluating Single Doses of ILV-095 in Healthy Subjects

NCT00822835 ↗

Phase 1 Completed 48 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of single doses of ILV-095 in healthy subjects.

Timeline

Start
2009-01
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator ILV-095 Unknown — Subcutaneous

Indications

No indication recorded.